110

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Symfi-Lo... Finally!

By Charles-Edouard!

Another litany of abuse... ICCARRE quickly!
The mithridatization, that is to say the progressive habituation to poisons, inhibitoids or inhibitors, does not remove the toxicity. It is less perceived, that's all!

Symfi-Lo = TLE-400

Symfi-Lo is the first drug to market the TLE-400(Tenofovir-Lamivudine-Efavirenz 400 mg) mitigation strategy. We discussed it in our post WHO proves us right! Well... The progress of this case will have been extremely slow, and the practical implementation is coming on the market: it is not too early! Something must have tipped off some people, and the Kirby Institute has obtained funding($11 million, if memory serves) from the Bill and Melinda GATES Foundation to launch the ENCORE-1 trial.

This involves reducing the dose of Efavirenz from 600 mg to 400 mg

Mylan launches Symfi-lo in the US.

TLE-400 unknown to the public

A few months ago, and this remains true today, a Google search on 'TLE-400' and HIV gave very few results. Actually only 2: a corporate and financial press release from Mylan (copied and pasted on financial websites) and... Charles-Edouard! Well... Now, there is a little more...

Obviously, this does not help the variety dealers... Let's also remember that it is not yet available in our country while the ENCORE-1 trial was published more than 5 years ago! And meanwhile, services are being closed to save money... Pffff...

Amazing recommendation and prioritization

When we allow, in a so-called recommendation document, a strategy that is obviously better, we are recommending it, without daring to say so.

Here is what Dr. Apollo in Harare, Zimbabwe, has to say about it:
Making the same drug with a little less of the same active ingredient is not an insurmountable industrial challenge! Well... We are not shocked that teenagers from the Third World are given priority... What shocks us is that at the usual rate, the French patient, who pays 600 Euros/month, will receive the cheaper and better tolerated formula... last! Isn't that a bit of an ass? You won't get it before 2-3 years, at best, while Mylan already claims 1 million users! We'll sell out... And who will be eating EFV 600 mg for months and months? It's you...

Morlat, Calmy: same error of judgment

And what does Morlat say about it ? He recommends it:

We have fun with it... First, he explains the 'constraint' of having to take 3 pills. As long as Symfi-Lo has not arrived in France, you're going to have a hard time! Secondly, why restrict yourself to patients who complain? When an overdose is useless, it is useless, even if it is tolerated. Useless is good French and it means what it says. Alexandra Calmy makes the same mistake, by doubling this restriction to patients who complain about a restrictive dosage condition. Well NO... Reducing the dose of VFE is clearly not a dosage restriction! Do you think they do dosing in Zimbabwe??? Prof. Calmy was wrong, and Symfi-Lo proves it, once again

Is 400 mg still too much?

Where is the trial at 200 mg, 300 mg or even 100 mg?

Who remembers that in the DMP 266-005 trial, 200 mg did BETTER than 400 mg or 600 mg? Who decided on 600? It was the manufacturer (DuPont Merck)... And no one, no one, has gone back to the drawing board with this univocal decision of the manufacturer. Why 400 and not 500? Because the 200 mg capsule packaging exists, so it's convenient to do a trial.

In fact, we had already reported the words of Pr Kiat RuxRungtham(youtube) who routinely does 300 mg. Well, it's time to ask the question of 200 mg in attack. As far as maintenance is concerned, we are in the midst of a frenzy: the 'threshold' doses are complete nonsense... We'll come back to this...

Dr. Joel Gallant: the moral and ethical fault

Dr. Joel Gallant, a drug promotion frontrunner and principal investigator for Gilead-sponsored trials, published an angry and threatening article condemning the ethical 'misconduct' of those benevolent physicians who bring Mono-DTG into their practice. It was ill-timed, remote-controlled, and in poor taste.

He was also seen ironizing about those patients who would prefer, conditionally, to preserve their psychedelic dreams and remain on Efavirenz. Ironically, to make fun of pharmaco-induced psychic suffering, which still causes thousands of suicides and depressions today, is abject and allows us to measure the immorality of the character.

To promote the latest novelty of Gilead, his sponsor, nothing stops him.

One would have thought that in his time, when he was practicing university medicine, he could have worked to reduce the deleterious effects of over-medication. This was not the case. In the DMP 266-005 trial, 200 mg did BETTER than 400 mg or 600 mg. The manufacturer, surrounded by experts(which ones?), had simply neglected this phase II trial. These trials are mandatory, they do it... Are they obliged to take them into account? Well no... You have to do an optimal dose finding trial and you are free to choose the maximum dose. And the deleterious effects? We don't care about that. Dosage is the doctors' problem. DMP 266-005 is to be thrown up.

And guess who was the principal investigator of DMP 266-005? Guess... Dr. Joel Gallant himself! Brrr, that's chilling... I hope that one day these people will be brought to trial...

In the news

- Luc Montagnier and Henri Joyeux launch a petition for precaution in medicine and health

- A study confirms the extent of the damage caused by Depakine. Depakine? That's what Siliciano is considering for his shock-and-kill... Brrr!

Feel free to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?

97% of patients overmedicated, 22 million without treatment ... Let's stop this scandal!

109

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



ICCARRE and the New Paradigm

By Charles-Edouard!

Jacques Leibowitch comments on our previous post:

The prevailing dogma is that ICCARRE is impossible. Some claim that we cheated (ANRS-4D = scathing denial). They dare to add that it is only for a few: Quatuor will sink them. Other idolaters say (e.g. Prof. Reynes): 'I hope it won't go any further...' It's laughable: for sure, it will go further... It is the virus that decides... not a mandarin...

Paradigm shift: demonstration at Pasteur

The trailer of the presentation at PASTEUR is on youtube, go there!
Leibowitch starts by presenting the classical picture in 2 steps:

1. Attack-Induction-Reduction:
Attack ARV treatment should in all cases:
- CONTINUOUSLY reduce CV < 50 cp
- Monitor < 50 copies/ml continuously
- Effectively stop any HIV-dependent progression to AIDS diseases
- Reduce the risk of intimate HIV transmission to almost zero
All this, today, in less than 6 months...

ICCARRE and its DISCONTINUTES can then be summoned...: we start the ICCARRian descent(typically 1 year after initiation of treatment)

2. Maintenance Treatment, following effective induction treatment, Cellular Activation and Peri-HIV Inflammation are in Leakage, the Lymphoid Environment is cooled down and HIV is reduced to a very small size in a biotope that is naturally not conducive to replication.

Pharmacokinetics in Failure: Thinking Outside the Box

It has been known for a long time that treatment cannot be stopped without seeing the CV rise. Viscontis could be an exception, the Pasteurians (Dr. Asier Saez-Cirion) have proposed a hypothesis. So they know that pharmacokinetics are insufficient to explain that repeated interruptions of 1 week can be done safely. Demonstrated by FAUCY, the boss of the American NIH. In a way, already announced by B. Autran, an eminent French immunologist.

Pharmacokinetics does not satisfy us, and, what is more, fundamental 'values' are false: Morlat continues to publish values that in Saint Antoine were said to be false (e.g. Nevirapine): Not only the theory is wrong, but also the values!

Parisian virology is wrong: we really need to change our paradigm!

The eternal restart as a new paradigm

Everyone agrees that there is a gap between infection and seroconversion. Typically 2 to 3 weeks. No one disputes that... Nobody... The post-treatment eclipse has been demonstrated many times.

So it's surprising that the virologists are still predicting an immediate rise in CV if you stop. Well... We are not surprised anymore, actually... Denying the eclipse is as stupid as the moon!

J. Leibowitch's proposal is to say that, post effective treatment and post interruption, HIV unwinds its initial film: it is the eternal non-return, the deficiency, of the primo, repeated as a bonus!

The reader will have noted that the unchanged repetition of the deficiency implies that the eclipse cannot be manipulated (it is a cosmic fact) and that the reservoir has nothing to do with it. The Choke-and-Mute is slightly different, it considers manipulating the eclipse and extending it. Here, Charles-Edouard and Leibowitch differ slightly. No matter... The Eclipse is here: let's take advantage of it!

Post-ARV eclipses as a repeat of two-rate HIV dynamics in vivo:

A- following a recent mucosal infection: primary inoculation
or
B- interruption of synergistic ARVs: chronic infection

It takes time for HIV to complete its reproductive cycle: slow local linear growth, as in difficulty to surface (primary infection) or resurface (post ARVs). Active forms of HIV remain sub-detectable for a while until... the delayed systemic exponential explosion...

Then, Jacques Leibowitch presented the trials and examples: ICCARRE is a proven, robust way. We will see this next time...

The French genius

I'm putting back the impressive pictures of the Bomsel team (also present at the seminar... ): a little to underline their technical prowess and also ours to have succeeded in putting it online...

That plus the availability on youtube of the presentation of Leibowitch... On the technical level, we are progressing!

Judiciarization

Patients file suit against Gilead. Below is a commentary from the Los Angeles Times


Here? No one told you about that... In any case, the enormous profits made are undoubtedly a breeding ground for dubious practices. We can find traces of what Gilead spends money on: ParisSansSida, ActUp-Paris, etc. It's up to you to make up your own mind...

Do not hesitate to comment, like, share and use

good weekend, good stuffing and not too many meds ... Huh?

108

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Choke and Mute: Seminar at Pasteur

By Charles-Edouard!

ICCARRE invited to the Pasteur Institute

Each presentation of Jacques Leibowitch or 4/7, in conference, arouses enthusiasm. Hugs, awards, laughter, congratulations, hearty applause, standing ovations: it never fails!

During IAS-2017, we had skilfully countered the deprogramming of ICCARE: Dr Turkova, not being shy, had slipped ICCARRE into her presentation. An invisible hand, not innocent, will have cut his entire presentation from the video session, in the editing. Well... It plays very small...

Parisian virology, mainly rotten, is nevertheless diverse, and the foundations of expensive and toxic 'medicine' has its detractors. Delelis has once again demonstrated that the classical dogma of the necessary integration into the DNA is incomplete and therefore false. Our biologists are saving the honor, even if their progress is hindered.

At Pasteur, we remember that the samples that allowed the famous discovery of the Virus (and 2 Nobel prizes) did not arrive at the Laboratory by themselves. The Pasteurian memory crosses that of ICCARRE at regular intervals. ICCARRE, dedicated, is also of interest to biologists: Dr. Olivier Schwartz, Scientific Director of the Pasteur Institute, thought it appropriate to invite J. Leibowitch to a dedicated seminar, on May 17, 2018. All the top brass of HIV biology were there: Pasteur, ENS, Inserm, Institut Cochin ... Françoise Barré-Sinoussi, always Pasteur at heart, would have been there if she had not been prevented from attending, which O. Schwartz was kind enough to ask us to excuse. No problem! Everyone, including you, will be able to view the presentations.

ICCARRE and the Paradigm shift

Pharmacokinetics could serve as a reasonable explanation for 5/7, but not at all for 1/7: we need to change the paradigm and revisit the foundations of HIV biology. With the exception of Dr. Hutter (Berlin), no doctor has ever cured a single (HIV/AIDS) patient. This should make us question ourselves a bit!

When thinking about ICCARRE, one should always keep in mind the characteristic curve of the Eclipse, otherwise one is on the wrong track. In 3 phases: down for a few days, then a sub-detectable rise, crossing the threshold of detectability to end in a spectacular ejaculation. Well... For those who have understood, it is obvious.

From ICCARRE to CHOKE-and-MUTE

Pierre Sonigo has explained many times to J. Leibowitch this dynamic chain reaction. For Sonigo or Kupieck, it is the basis of a(systemic?) biology, so fundamental and general, that they do not bother to popularize the HIV-specific version. J. Leibowitch takes it up in his book 'Pour en finir avec le Sida'. It deserves some light, which is normal for an eclipse.

The The prevailing dogma is a misconceptionand the best way to fight a misconception is to come up with a visibly better one!

It is here that yours truly, inspired by his masters, had the idea to create a didactic tool: it is the Eclipse Equation, which Leibowitch commented, rightly so:


Well done! Thus, we are going to make the New Equation of the Eclipse which exposes a way to remission, alternative to the dominant theory. Dominant... and failing, need we remind you?

Here is how, for the sake of clarity, appears on a popularizing blog an innovative concept, baptized by us theChoke-and-Mute. Indeed, ICCARRE, beyond the anecdotal relief (the 4/7, small arm), is a way to Remission! It is even an obligatory step: how could a patient who fails the 1/7 succeed the 0/365? Pass ICCARRE 1/7 and then we'll see!

Choke and Mute: Baptism at the Pasteur Institute

The paradigm shift made necessary by 1/7 goes hand in hand with a new theory of remission. The one cannot go without the other... Hence the idea of exhibiting them together in Pasteur. But then, in Pasteur, the holy of holies of world biology, you can't miss it! And it's May 17 or never, it's in a few weeks, and if the scientific direction of Pasteur is willing... Oh dear! What a challenge!

The text has been worked on, amended and revised. It remains to integrate it to Leibo's PowerPoint. Argh!!! We are caught by time! Catastrophe, it's now or never! It's for a seminar at Pasteur, and Leibo is polishing his slides, the paradigm shift. Oh! No time for Choke-and-Mute...

Disaster in the making! And we are saved: O. Schwartz accepts the principle of 2 presentations: the paradigm shift, by Leibo, and the Choke-and-Mute by... Charles-Edouard!... And that, from one day to the next!

Choke and Mute: Applause at Pasteur

Well... Despite some technical difficulties (ah... computers...) and with the help of the Pasteurians, we did great! It was really great!

We have to admit that ICCARRE, the 4/7, the Morlat recommendation, ANRS-4D, Quatuor, paradigm shift, the Eclipse, its equation, the Choke-and-Mute, and a plea for ICCARRian research, all in 1 hour, it's dense!

In a small seminar, with a learned and specialized audience, it's a good thing! Thanks to all! The hearty applause was our reward! Oh, it's clear! We have changed dimension!

The videos will be online soon

The presentations will soon be available online, in replay, once the English versions are finalized. To have them, in trial version, please leave an email address in the comments (your address will not be published).

In the news

Let's be modest: the news that counts is us! There was also:

- Immunology/Cancer: CAR-T cell breakthrough confirmed

- Finally... Finally! The first commercial 'lighter' has arrived on the market. It is the TLE-400 that we were talking about here. You will notice that nobody else is talking about it... Hi, Hi, Hi.... And Mylan introduces CimDuo ... This will do our finances a world of good, including PreP...

The French genius

Impressive images:
Live imaging of HIV-1 transfer across the virological synapse the T4 cell by Fernando Real et al. (and Morgane Bomsel, incidentally present at the seminar... )

List of videos (to be viewed separately)

- Video #1
- Video #2
- Video #3
- Video #4
- Video #5
- Video #6
- Video #7
- Video #8




Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!

107

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Isentress HD®: 10 times the dose!

By Charles-Edouard!

Isentress HD®, programmed overmedication: 10 times the dose!

With a 1/2 pill strategy, the patient reduces by 2 and is amazed! Instead of a massive dose, she takes a 1/2 dose... massive! How can we judge a reduction without knowing how much we have been cheated? The phase 2 studies should enlighten us... Not at all. Sometimes not published (ex. Efavirenz), they are systematically ignored by the manufacturer and the 'authorities': the maximum dose is always retainedI don't know of any exception. That's how we have 600 mg of EFV, 600 of ABC or 50 of DTG: the tests show that it's too much, but they sit on it! What is the use of testing!!! What is the use of 'authorities' if not as a registration chamber.

The first overmedication is theAbusive Indication Extension; we will come back to this... Another is not to differentiate between attack and maintenance. Let us mentionICCARRoPhobia, MonoPhobia or DemiPhobia.

The arrival of Isentress HD ® will reveal a spectacular increase in dose for the sole benefit of a commercial strategy. We say 10 times the dose, and we will demonstrate it.

Before the marketing of Isentress HD at 1200 mg(sic), we anticipated a drop of the dose.

Marketing will take advantage of a possible drop to twice a day to increase the dose tenfold in order to make it a once a day dose. The reformulation of Raltegravir into r-RAL shows a tripling (at least) of the dose; the too discreet pharmacokinetic tests show that the dose is at least 5 times higher. Finally, the methodological error, a la Levothirox®, shows that this factor, of at least 5, will be 10, in practice. And everyone will see nothing but fire. Your liver will pay for it!

r-RAL: proof by Dutrebis®.

RALTEGRAVIR poses a major problem of bioavailability, discussed here. In maintenance, there are 3 ways to take it: Merck style (1 tablet twice a day), German style (2, once a day), Italian style (chew 2 tablets, once a day). The tablet disintegrates badly in the stomach, its only opportunity to pass into the bloodstream, and then passes into the intestine, as if you had not taken anything! If, let's say, one out of two doses is missed, well, let's take two doses... And obviously, not at the same time. It's the same stomach... So to make sure, we will increase the dose, without taking into account that the phase 2 validated the 100 mg!

Merck's galenists will know how to improve the bioavailability: they will not say anything about it, or rather, they will not put it on the market... French. To disguise their feigned innocence, they are making a RAL/3TC combination. Lamivudine at 150 mg and RAL at... 300 mg, instead of 400: Dutrebis&reg, approved by the FDA and theEMA. No ?!! Yes!!!

Merck simply demonstrates better bioavailability. No clinical trial, too expensive: the collection of data where Dutrebis® has been distributed may be enough for the manufacturer.

Lamivudine is free, the RAL dose is reduced by 25%, so logically, its marketing would have been a loss of profit for Merck. Merck does not market it and the patients' associations, under perfusion, do not even ask for it!

r-RAL: the reformulated RALTEGRAVIR, better, not marketed...

The dose officially reduced, we will substitute 3TC with r-RAL, and make do with r-RAL alone.

The opportunity is very good: since we can reduce the dose, ensure a better bioavailability, bring everything down to a once-daily dose (QD), we hope to defend our position on the market, and, to do so, we are going to... raise the dose!

r-RAL: the pharmacokinetic proof

For a concentration, just before the new intake, equivalent to the old one, the dose must be increased: it is taken in one go. Because of the half-life (6-9 hours), it is necessary to multiply by... 4. Compared to 400 mg (BID), it would have been necessary to make 4 x 400 or 1600 mg(yuck... ), after 6 hours, there remains the equivalent of 800, and after 12 hours, the equivalent of 400 mg, that is to say what we had before... All is well!
On paper, 1600 mg is indigestible... But here, since we can do with r-RAL (300 mg) what was done with RAL (400 mg), only 1200 mg are necessary. It's yucky... But in 2 tablets of 600 mg, it becomes feasible. By taking 1200 mg you don't realize what it's like to take 1600 mg of the previous formula.

Obviously at 1200 mg of r-RAL, the patient gets a nasty boost: the peak concentration will be 4 times higher! 4 times! Four times? No, Charles-Edouard, you are forgetting that we have improved the bioavailability by 25%, so your peak will not be 4 times higher but 5!

Oh the ugly calculation! Let's go see in vivo. Merck published it: multi-dose study of Raltegravir formulations.

At first sight, the peak with r-RAL seems slightly higher than with RAL. Beware! This is a LOG scale! So the pic r-RAL is 5 times that of RAL!!!

r-RAL: 5 times the peak!? No... at least 10!

Imagine if we multiplied by 5 the Efavirenz peak... It's a guaranteed depression/suicide: an overmortality that would be visible(and yet... it would be well hidden...). Well... If we increased the peak of EFV, we would have the usual morons telling us, what they already do, that we have to take it on an empty stomach, or in the evening, or 2 hours before going to bed, or changing creamery, etc...

At 5 times the peak, we understood the topo! But 10 times?! Where does that come from? Where do you get that from? 5, I see... but not 10...

Be patient, my little rabbit... 5 is what you will have seen... Because it has been cleverly made up to you like this... You have seen, but not all of it....

To see it clearly, let's follow closely the Levothyrox® scandal(Merck, again), which the manufacturer, clinicians and 'authorities' (and the 'minister' Buzyn) will have denied en bloc. Some are clever, others gullible morons. Come on, marketing 'tricks' are tiring, we'll see next time... Go ahead and read Dr. Dupagne's truly organic equivalent #1? and #2.

In the news

- Abusive Extension of Indication: Hypothyroidism: some people treated wrongly. 3 millions take Levothyrox®: an absolute aberration... We are only surprised now ???

- Foolish practice of medicine, homeopathy: new complaints. The defense of these charlatans? Suing for non-confraternity. Let us finally decide on the merits!

- Abacavir cleared by its opponents, in spite of themselves. They advanced in camouflage, armed with smoke and mirrors, and the maneuver was foiled. For the French patient, there is no excess cardiovascular risk and the hypothesis of a mechanism of action is taking on a life of its own. We will come back to this...

The French genius

It seems that French research is making fundamental discoveries:
- Descourt / Benkirane and their reservoir marker: CD32a is a marker of a CD4 T-cell HIV reservoir
- Delelis with his 3'PPT mutation
- Estaquier, interviewed here, and his published work: Anti-caspase Q-VD-OPH prevents progression to AIDS in macaques



Feel free to comment, like, share and use

Have a good weekend, good stuffing and not too many meds ... Huh?

106

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Happiness regained

By Charles-Edouard!

Here is one who has almost understood everything (well... he is discovering...):

- 3 strategies are in competition: Mono-DTG, ICCARRE or 1/2 pill

- virologists betray the trust of those who come out of the closet. Always!

The 'advisors' (stipendiaries) who invite you to trust them systematically deceive you. HIV creates an asymmetrical power relationship. Don't be naive... The doctor writes the prescription. Regain autonomy? The key is the stock! We build it, without saying anything. Mono-DTG = no stock but ICCARRE or 1/2 pill, yes! Thus, the doctor does you a favor and you can, in the long run, build up your stock and regain your freedom: ICCARRE (or 1/2 tablet), in autonomous mode, allows you to fight against ICCARRoPhobia. Long live ICCARRE-Free!

Testimony of a new found happiness

Thanks for the news! Dybyl and Faucy are the forerunners of x/7. By not pursuing it, they secured a career (director of the global fund and NIH, respectively). Having your finger on the atomic button allows you to negotiate anything you want. Just ask Kim Jun Un!

Quartet and Liberation Day

Truchis or not Truchis, ICCARRE x/7 is an inevitable Darwinian evolution...
In 4/7, the Liberation Day is Friday, July 27th! In 2/7, it was Saturday April 14th! From this day on, you are no longer the obliged slave of Gilead, ViiV, and their accomplices.

There are 240 days left before the announcement of the success of Quatuor phase I: the first 320 patients have already spent 4 months without a single announced failure! We are on the right track! With or without Truchis! I put a countdown on the top right corner.

To the obligation of treatment

Laurent Wauquiez wants to make chemical castration mandatory for ...!!! Not long ago, we chemically castrated... homosexuals(cf Turing) and this despite the Nuremberg code. It makes you think, doesn't it ?

Judiciarization

The stop of the marketing of Videx® by BMS will put a hundred patients, in therapeutic success, in a dead end! The ANSM has deceived you by announcing a generic, the Seronegs associations, acting as a patient association, are not saying a word. The only recourse: Justice. So preparations are being made for this: formal notice, lawyers, etc.

In the news

- Cigarette prices: manufacturers do not want to 'kill the goose that lays the golden eggs

- MK-8591, an NRTTI (not NNRTI...) could allow for weekly commercial catch; that is, adding the eclipse, 1/15!

- A brilliant idea has just appeared on the tickers: Juluca ® + Descovy ® in 1/7. 2 small pills taken weekly. It smells like a good plan! We'll come back to it...

- We could reformulate Efavirenz to dose at 100 mg

The French genius

I put you an exchange between Garches and a thing, the TRT-5, whose utility escapes me... French genius (?!)...
- The initial questions
- the answers provided by Garches

Find Jean Marais, so right when he says: By the way, don't you think it's strange that everyone tries to be physically beautiful, while it's possible for anyone to be morally beautiful and no one does it (on Youtube, at minute 1:40)

Another version of C. Franck's Fugue: Latry, on the organ.

Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!

Essai pour Tests: NE PAS EFFACER

Essai-20220417-151413

105

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Choke and Mute #2

By Charles-Edouard!

Here is the nice month of May. Tribute to Cora Vaucaire...

I will always love cherry time, and the memory I keep in my heart

Towards a new Eclipse Equation

We saw in the previous post how the Eclipse equation, basic, responds well to known phenomena. History shows us that a new theory emerges by refutation of the old ones: the universal theory of gravity (Newton) is a refutation of Descartes, the theory of Evolution (Darwin) a refutation of William Paley, the theory of relativity (Einstein) a refutation of Newton. Einstein who made 2 theories on the same subject...

The 'Shock-and-Kill' strategy is very well understood when reading our basic Equation. However, we have already tried the Shock-and-Kill for a good fifteen years and we can't do it! When something doesn't work, we can start with the idea that it doesn't work because we didn't try hard enough, that we need more! Europe doesn't work, it's because there is not enough of it! AZT doesn't work: we increase the dose! We know the story. 'Insanity is repeating the same mistakes and expecting different results'(amusing article on this subject)

ICCARRE 1/7 (or even 1/15) works, without theory: competence without understanding. Our goal will be to improve the Eclipse Equation, in order to account for ICCARRE.

New equation with epigenetic distribution

The basic equation does not account for ICCARRE nor for the attrition of the reservoir by incorporation of R263K mutants, due to DTG (Mesplède lab manip).

An additional variable is introduced to account for the epigenetic availability to contribute more or less quickly to the rebound. Below a certain level of activity, infected, latent CD4 cells are considered as potential contributors independent of each other. Once replication resumes, the whole thing goes haywire, in an explosive chain reaction. The system enters phase 3 (explosive) and we leave the domain of validity of the Equation. The term introduced is called EpigeneDist. Epigenetic because it is epigenetic by nature, Dist because it is a distribution.

When measured repeatedly, in the same patient, by successive analytical interruptions, the eclipse is substantially always the same.

EpigeneDist: a promptness distribution

EpigeneDist. reports a distribution of readiness to initiate the viral rebound. If it is in the form of, for example, a distribution function, we will obtain a distribution of the duration of the Eclipse, whereas it is rather a constant. EpigeneDist is therefore more likely to be an arithmetic, geometric or higher moment average. EpigeneDist is not a distribution function per se, but the synthetic representation of this diversity. The underlying distribution is a stochastic randomness (a stochastic process is a random function, its argument is time, with an irreversible and ineluctable course).

The proposal that the eclipse can be lengthened, by introducing mutants with reduced fitness, for example R236K by DTG, exists elsewhere, on paper and in test tubes.

At the same time, it has been proven (ICCARRE) that a progressive reduction of the number of doses can be proposed, thus opening the duration of non-taking from 3 to 4 days, then to 5 or 6. EpigeneDist is a duration. The longer it is, the longer the Eclipse is: it is therefore in the numerator

The new equation allows to account for the opening of the Eclipse by progressive methods aiming at eliminating the proviruses which are the most prompt to start a replication.

Charles-Edouard: The Book!

The systematic hostage-taking of immunocompetent seropositives by militant and stipendiated seronegs deserves a strong response. It will take us 1 to 2 years... The project 'Charles-Edouard: The Book!' is launched... The book will be free and available on the Internet. It's a work in progress... As usual...

For now, there is already a page!

Towards the obligation of treatment

Here is what will incite to enter in the treatment: the right to forget is going to be opened to the seropositives. It is important to understand 2 things: It is in the objective interest of the associations of Seronegs to make the treatment 'compulsory' and that the 'patients' associations are no longer directed by Seropositives. There you go, the world becomes intelligible again. What will the 'Elite Controllers' patients do? Or the immunocompetent-untreated? One man's right leads to another's obligation... Stay tuned, you are not safe from surprises!

In the news

- Videx, prescribed as the 4th molecule, is it over? Well, that's just great! Hard for those who can't take Abacavir or Tenofovir. The anti-ICCARRE morons have won this round. You'll have to get it far away (e.g. Red Cross in Thailand) or substitute ABC(most likely) or TDF. I have never used Videx, I warned my readers! We can also replace it with DTG, if experience, once again, contradicts pharmacokinetics, now demonetized... Ah, the time when Act-Up was claiming is long gone! (see the video!)

- ActupParis: the management was kicked out by ... the activists... It is true that Act-Up-Paris had admitted that it could not face the financial disengagement of ... Gilead, which was 45.000 Euros!

- The ANRS has published on the effects of a caspase inhibitor. Thescientific article is here.

The French genius

When you're in the cherry season
If you're afraid of heartbreak
Avoid the beautiful

Miyazaki fans will love this version in Porco Rosso (youtube)

See the excellent video by Dr. Rahbi: Manipulating numbers and doctors

Feel free to comment, like, share and use

Have a good weekend, good stuffing and not too many meds ... Huh?

104

This was originally published here, in French (link).
We provide this translation for your convenience. Practical aspects may differ where you live.



Choke and Mute: ICCARRian Remission

By Charles-Edouard!

Condensed from the blog of Dr. Christian Lehmann:

Well said! As early as 2002, Dr. M. Girard had predicted the extended vaccination obligation... Today, everything is in place for the obligation of overmedication...

CHOKE-and-MUTE: a new approach to remission

CHOKE-and-MUTE is a new approach to remission, already clinically proven. We are working on its experimental modeling...

Summary:
- Eclipse equation
- New equation with epigenetic distribution
- Stochastic modeling and the Choke-and-Mute mechanism
- Comparison between remission strategies (cure)
- Why a theory is needed
- Why basic research is needed

The Eclipse: so many times observed

In the suppressed and stable patient, the resumption of viral activity is delayed. The rebound is initially nil, then starts, and finally explodes until it reaches levels similar to the Zenith without treatment. The image of a total eclipse of the Sun by the Moon is relevant, except that the non linear phase of the viral explosion is exponential (limited)

In the Choke-and-Mute strategy (ICCARRE), we maintain the infra-detectability: only the first 2 phases are of interest (red line above)

Eclipse equation

To account for the 2 phases (pharmaceutical persistence and takeoff), we formalize a 2 components equation. We have described it here and exposed its simplified form:

Eclipse equation and pharmacokinetics

This equation is a good representation of known phenomena. First of all, pharmacokinetics... The arrival of long-lasting N/NRTIs is announced: Elsufavirine, already approved in Russia and another one by Merck: MK-8591 (EFdA ) (to compare with the other new products). The manufacturers will, in any case, look at weekly dosing and counter the arrival of injectables. We already know how to make the weekly dose. Tomorrow, there will be a multitude of commercial options

Eclipse equation and Elite controllers

The equation also accounts for Elite controllers and controllers, where the eclipse is infinite or very long...

Eclipse equation and non-competent proviruses

The Eclipse equation accounts well for the integration of non- or low-competent proviruses (in particular unspliced vs. multiplied RNA, which may account for the particular success attributed to Nevirapine)

This is somewhat analogous(but not quite) to the Wainberg proposal to replace the virus with a much less available R263K mutant.

Eclipse equation and Berlin patient

When susceptibility is zero, the eclipse becomes infinite: this is the case in the cure of the Berlin patient; this is the strategy of CCR5 inhibitors. This is probably one of the serious leads for static remission (without episodic maintenance)

Eclipse equation and prolonged control

Prolonged control exists, it is documented in 2-3% of patients treated for a long time. If we go looking for them, we find them... If, if... we will come back one day... It is also possible in(some, not all) patients with very low reservoirs. For example the Toronto patient, also known as the CHUN patient and the rare Viscontis. The same CHUN that, on the contrary, showed that a very low reservoir was not sufficient to allow a sufficient truce. This term is probably conditional on something else... But what?

New Equation with epigenetic distribution

The basic equation is very useful. To account for ICCARRE or the attrition of the reservoir by incorporation of R263K mutants, due to DTG (Mesplède lab manip), it must be made to live.

So we have to complete our basic equation, which we will do next time...

Judicialization to counteract the obligation to treat

Our way of thinking will collide with a new objective of the medical-pharmaceutical mob: the obligation of treatment.

- To the chapter Morlatan-you-are-deceiving, you can add a documented error, by a factor of 4(at least!) on the threshold concentration of Nevirapine. We will come back to this...

In the news

- drug-induced depression is a brain injury, not just a passing mood. HAND also: Aberrant occipital dynamics differentiate HIV-infected patients with and without cognitive impairment

- Dr. Asperger was a eugenicist... Well... Who wasn't then? You will see how the treat-all hysteria will break and carry away the Nuremberg code...

- A. Faucy's surprising comment on the usefulness of a low efficiency vaccine. This guy is a Kador, we are told: he effectively launched, then buried, the short cycle... Low efficiency vaccine = creation/fixation of new mutants! Bravo!!!

The French genius

It is the year of Debussy... So I propose a César-Franck break, with Lugansky(Prelude, Fugue & variation), the purists will be touched by E. Power Biggs on the organ. There are so many adaptations. This one, on sax, is touching...

Enjoy also S. Rodriguez (Rachmaninoff) before it disappears... Thanks to

Feel free to comment, like, share and use

97% of patients overmedicated, 22 million without treatment... Let's stop this scandal!